The ability to deliver therapeutics site—specifically in vivo—remains a major challenge for
the treatment of malignant, inflammatory, cardiovascular, and degenerative diseases. The
need to target agents safely, efficiently, and selectively has become increasingly evident
because of progress in vascular targeting. The vascular endothelium is a central target for
intervention, given its multiple roles in the physiology (in health) and pathophysiology (in
disease) and its direct accessibility to circulating ligands. In cancer, the expression of …